ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−3.58%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- $2.5M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.09
- EPS estimate
- -$0.09
- Revenue actual
- —
- Revenue estimate
- $31.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +24.6%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $5.50
- PT range
- $2.00 – $9.00
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.09 | -$0.09 | Miss -2.86% | — |
| May 7, 2026 | -$0.13 | -$0.06 | Beat 53.85% | — |
| Nov 5, 2025 | -$0.17 | -$0.13 | Beat 23.53% | — |
| Aug 7, 2025 | -$0.21 | -$0.16 | Beat 23.81% | — |
| May 14, 2025 | -$0.25 | -$0.17 | Beat 32.00% | — |
| Feb 28, 2025 | -$0.25 | -$0.27 | Miss -8.00% | $244.5K |
| Nov 7, 2024 | -$0.25 | -$0.25 | In line | — |
| Aug 1, 2024 | -$0.14 | -$0.28 | Miss -100.00% | — |
| May 2, 2024 | -$0.08 | -$0.14 | Miss -75.00% | — |
| Mar 7, 2024 | -$0.21 | -$0.08 | Beat 61.90% | $392.6K |
| Nov 3, 2023 | -$0.24 | -$0.14 | Beat 41.67% | — |
| Aug 3, 2023 | -$0.31 | -$0.15 | Beat 51.61% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026